# Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI

> **NCT02328443** · PHASE1 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Midazolam
- **DRUG:** itraconazole
- **DRUG:** rifampicin

## Key facts

- **NCT ID:** NCT02328443
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02328443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02328443, "Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02328443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*